Kane Biotech Inc.
KNE.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 56.78% | 1,133.19% | -16.59% | -104.41% | -32.57% |
| Total Depreciation and Amortization | -23.77% | -10.59% | -10.49% | 7.03% | -9.90% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -80.63% | -1,172.22% | 3,176.47% | -2,531.84% | 180.21% |
| Change in Net Operating Assets | -74.78% | -528.40% | -22.09% | -36.15% | 78.24% |
| Cash from Operations | 26.03% | -656.99% | -2.92% | -380.21% | 29.84% |
| Capital Expenditure | -76.19% | -- | -- | -1,666.67% | -40.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 88.84% | -759.73% | 57.61% | 45.76% | 57.50% |
| Cash from Investing | 74.59% | 15,224.94% | 16.30% | -41.07% | 54.98% |
| Total Debt Issued | -- | -- | -- | -- | 52,531.58% |
| Total Debt Repaid | -1.05% | -3,951.02% | -657.25% | -507.97% | -372.98% |
| Issuance of Common Stock | -40.12% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 63.59% | -8,860.13% | 886.43% | 221.00% | 79.44% |
| Cash from Financing | -93.50% | -4,332.29% | -5.22% | 316.22% | 654.92% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -195.95% | -536.40% | -61.48% | -466.26% | 136.34% |
